Status:

COMPLETED

The Heart Hive COVID-19 Study

Lead Sponsor:

Imperial College London

Conditions:

COVID-19

Cardiomyopathies

Eligibility:

All Genders

18+ years

Brief Summary

All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment. The HeartHive COVID-19 study is an international onlin...

Detailed Description

The impact of the COVID-19 pandemic on patients with cardiomyopathy has not been explored and represents a critical unmet need. Insights into exposure, healthcare outcomes, behavioural changes and the...

Eligibility Criteria

Inclusion

  • Adult (age 18 and over) Males or Females
  • Capacity to provide informed consent
  • Subjects with either:
  • A self-reported confirmed diagnosis of cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, restrictive cardiomyopathy, left ventricular non-compaction cardiomyopathy) Or
  • No self-reported history of heart disease
  • Note: Pregnant women are eligible. This study is observational and entirely separate from clinical care.

Exclusion

  • \- Patients who lack capacity to consent for themselves Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill)
  • \- Although usually considered a vulnerable group, pregnant women are eligible for this study which is observational and entirely separate from clinical care.
  • Patients with a confirmed history of coronary artery disease:
  • who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery disease, or
  • who have undergone previous percutaneous coronary intervention or coronary bypass surgery History of primary valvular heart disease or congenital heart disease Severe, untreated or untreatable hypertension (systolic blood pressures routinely \>180 mm Hg and/or diastolic blood pressures \>120 mm Hg)

Key Trial Info

Start Date :

July 26 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 21 2022

Estimated Enrollment :

267 Patients enrolled

Trial Details

Trial ID

NCT04468256

Start Date

July 26 2020

End Date

July 21 2022

Last Update

November 9 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Imperial College London

London, United Kingdom, W12 0NN